Shares of biopharmaceutical company Praxis Precision Medicines Inc. are soaring, boosted by the successful trial of a new drug to treat movement disorders.

The drug, ulixacaltamide, targets

essential tremor, a difficult-to-treat nervous-system condition that causes rhythmic shaking and can affect any part of the body, but typically affects hands.